EGenesis Stock
EGenesis designs xenotransplantation for the benefit of human health.
Sign up today and learn more about EGenesis Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About EGenesis Stock
EGenesis designs xenotransplantation for the benefit of human health. Its technology helps transform xenotransplantation into a medical procedure, enabling clinical researchers to address the global organ shortage.
Funding History
| August 2016 | $2.0M |
|---|---|
| March 2017 | $38.0M |
| November 2019 | $100M |
Management
Chief Operating Officer
Kenneth Fan
Executive Vice President of Research and Development
William Westlin
Chief Scientific Officer
Luhan Yang
Chief Executive Officer
Paul Sekhri
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
